Adaptimmune
Adaptimmune is a biotechnology company specializing in the development of T-cell-based therapies for cancer treatment, with a focus on engineering patients' own cells to combat solid tumors.
Company Overview
Adaptimmune develops T-cell-based therapies for the treatment of cancer. The company focuses on engineering a patient's own cells with its proprietary cell therapy platform to combat cancer. Adaptimmune's innovations are centered on leveraging the immune system to target and eliminate cancer cells effectively. The company's research and development efforts primarily target solid tumors, aiming to provide new therapeutic options for patients.
T-cell Therapy Development
Adaptimmune specializes in engineered T-cell therapies targeting solid tumors. The company has submitted its first Biologics License Application (BLA) to the FDA for a T-cell therapy in solid tumors, marking a significant milestone. Their pipeline includes multiple engineered T-cell therapies aimed at providing treatment solutions for various types of solid tumors. This demonstrates their commitment to exploiting the therapeutic potential of T-cells in cancer treatment.
Proprietary Cell Therapy Platform
Adaptimmune employs a proprietary cell therapy platform that involves engineering a patient's own T-cells to enhance their cancer-fighting capabilities. The manufacturing process includes procedures such as leukapheresis and the delivery of affinity-enhanced T-cell receptors (TCR). This platform aims to create customized treatments tailored to individual patient needs, thereby optimizing therapeutic outcomes.
Global Presence
Adaptimmune operates offices in Oxfordshire and Stevenage in the UK, as well as in Philadelphia in the US. Additionally, the company maintains a dedicated Good Manufacturing Practices (GMP) vector manufacturing space in the UK through an agreement with Cell and Gene Therapy Catapult. This international presence supports its research, development, and manufacturing efforts across different regions.
Collaborations and Partnerships
Adaptimmune collaborates with prominent organizations such as Alpine Immune Sciences, Genentech, and MD Anderson Cancer Center to enhance its platform capabilities and accelerate product development. These strategic partnerships play a crucial role in advancing Adaptimmune's research initiatives and expanding its therapeutic offerings. Moreover, the company engages with patient organizations to provide financial support and promote education and awareness initiatives related to cancer treatment.